RxDoctor Payments Data

Edward Elliott

Family · Franklin, TNNPI 1518412105

Payments from drug & device makers

$6,565in general payments, 2019–2025

Across 351 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$885
  • AstraZeneca$705
  • AbbVie$620
  • Amgen$420
  • Bayer$272
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,46598%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,565 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$43,829
Medicare patients
195
Services billed
1,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin44$69,931
OzempicSemaglutide50$57,475
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$43,412
FarxigaDapagliflozin Propanediol47$42,742
EliquisApixaban31$26,899
JanuviaSitagliptin Phosphate23$21,770
RybelsusSemaglutide17$17,316
MounjaroTirzepatide13$14,678
MyrbetriqMirabegron20$12,067
Albuterol Sulfate HfaAlbuterol Sulfate124$2,903
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,832
Gabapentin121$2,227
Omeprazole109$1,770
Atorvastatin Calcium180$1,711
Losartan Potassium84$1,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,612$74,79167 claims
Boehringer IngelheimJardiance$184$69,93144 claims
GSKTrelegy Ellipta$136$43,41234 claims
AstraZenecaFarxiga$705$42,74247 claims
PfizerEliquis$266$26,89931 claims
MerckJanuvia$39$21,77023 claims
Lilly USA, LLCMounjaro$885$14,67813 claims
Astellas Pharma US IncMyrbetriq$130$12,06720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.

Other family in Franklin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →